NCT04572763 2026-01-07
Copanlisib Plus Venetoclax in R/R DLBCL
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT03884998 2025-12-30
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase 1 Active not recruiting
NCT04433182 2025-08-08
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
Fondazione Italiana Linfomi - ETS
Phase 2 Terminated
NCT03484819 2025-03-03
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT04933617 2024-07-09
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT04263584 2024-01-05
COPA-R-CHOP
University Hospital Muenster
Phase 2 Unknown
NCT04156828 2023-06-29
Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
University of Washington
Phase 1 Terminated
NCT02391116 2019-01-04
Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Bayer
Phase 2 Completed